Key result
Platelet glycoprotein IIb/IIIa antibody fragment completely blocks new thrombus formation in preclinical model.
Why the study?
The antithrombotic effects of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor were evaluated in an established animal model of acute platelet thrombus formation.
Supports GP IIb/IIIa blockade for thrombosis prevention; leaves open translation to human trials.
A murine monoclonal antibody directed at the platelet glycoprotein IIb/IIIa complex, which blocks platelet aggregation ex vivo, was tested for its antithrombotic effects in an established animal model of acute platelet thrombus formation in partially stenosed arteries. Infusion of 0.7 to 0.8 mg/kg of the F(ab')2 fragment of the antibody completely blocked new thrombus formation despite multiple provocations, making it the most potent antithrombotic agent tested in this model.
No takes yet. Share an insight, caveat, or question.
Coller et al. (1986) studied Acute platelet thrombus formation in partially stenosed arteries. F(ab')2 fragment of a murine monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor was evaluated on New thrombus formation despite multiple provocations. Infusion of 0.7 to 0.8 mg/kg of the F(ab')2 fragment of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor completely blocked new thrombus formation in an animal model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: